company background image
FP10 logo

Salarius Pharmaceuticals DB:FP10 Stock Report

Last Price

€3.01

Market Cap

€2.0m

7D

0%

1Y

-48.5%

Updated

10 Sep, 2024

Data

Company Financials +

Salarius Pharmaceuticals, Inc.

DB:FP10 Stock Report

Market Cap: €2.0m

FP10 Stock Overview

A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. More details

FP10 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Salarius Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Salarius Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.01
52 Week HighUS$6.40
52 Week LowUS$2.74
Beta0.96
1 Month Change0%
3 Month Change0%
1 Year Change-48.49%
3 Year Change-98.23%
5 Year Change-99.75%
Change since IPO-99.88%

Recent News & Updates

Recent updates

Shareholder Returns

FP10DE BiotechsDE Market
7D0%-0.8%-1.6%
1Y-48.5%-13.0%6.8%

Return vs Industry: FP10 underperformed the German Biotechs industry which returned -17.3% over the past year.

Return vs Market: FP10 underperformed the German Market which returned 3.9% over the past year.

Price Volatility

Is FP10's price volatile compared to industry and market?
FP10 volatility
FP10 Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: FP10 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine FP10's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a2David Arthurwww.salariuspharma.com

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.

Salarius Pharmaceuticals, Inc. Fundamentals Summary

How do Salarius Pharmaceuticals's earnings and revenue compare to its market cap?
FP10 fundamental statistics
Market cap€1.97m
Earnings (TTM)-€5.86m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FP10 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$6.46m
Earnings-US$6.46m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.49
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did FP10 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/10 17:00
End of Day Share Price 2024/06/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Michael KingH.C. Wainwright & Co.